Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Summary: Background: The 2013-15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a...
Sparad:
Huvudskapare: | , , , , , , , , , , , , , , , , |
---|---|
Materialtyp: | Bok |
Publicerad: |
Elsevier,
2017-03-01T00:00:00Z.
|
Ämnen: | |
Länkar: | Connect to this object online. |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
Signum: |
A1234.567 |
---|---|
Exemplar 1 | Tillgänglig |